Skandinaviska Enskilda Banken Ab (Publ) Mirati Therapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $380,471 - $565,225	9,061 Added 68.96%	22,200 $1.3 Million
Q3 2023 Nov 09, 2023	SELL	$27.8 - $45.35 $978,949 - $1.6 Million	-35,214 Reduced 72.83%	13,139 $572,000
Q2 2023 Aug 07, 2023	SELL	$36.13 - $49.49 $1.68 Million - $2.3 Million	-46,559 Reduced 49.05%	48,353 $1.75 Million
Q1 2023 May 11, 2023	SELL	$36.54 - $54.26 $21,302 - $31,633	-583 Reduced 0.61%	94,912 $3.53 Million
Q4 2022 Feb 08, 2023	SELL	$41.27 - $98.62 $1,650 - $3,944	-40 Reduced 0.04%	95,495 $4.33 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $2.42 Million - $3.53 Million	40,693 Added 74.2%	95,535 $6.67 Million
Q1 2022 May 11, 2022	SELL	$75.82 - $150.97 $2,047 - $4,076	-27 Reduced 0.05%	54,842 $4.51 Million
Q4 2021 Feb 10, 2022	BUY	$132.01 - $190.29 $44,091 - $63,556	334 Added 0.61%	54,869 $8.13 Million
Q3 2021 Nov 10, 2021	SELL	$132.13 - $177.45 $1.73 Million - $2.32 Million	-13,098 Reduced 19.37%	54,535 $9.65 Million
Q2 2021 Aug 10, 2021	BUY	$144.0 - $179.73 $8.46 Million - $10.6 Million	58,774 Added 663.44%	67,633 $10.9 Million
Q1 2021 May 14, 2021	BUY	$158.92 - $221.61 $1.41 Million - $1.96 Million	8,859 New	8,859 $1.52 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.